Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OPTN 10.16.2024

Full Press ReleaseSEC FilingsOur OPTN Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
  • 12.26.2024 - Optinose Announces 1-for-15 Reverse Stock Split
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.15.2025 - 8-K Current report
  • 01.15.2025 - EX-99.1 EX-99.1
  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities

YARDLEY, Pa.,Oct. 16, 2024(GLOBE NEWSWIRE) --OptiNose, Inc.(NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment withOptiNose. The stock option awards were granted outside of theOptiNose, Inc.2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to the new employees on their respective hire dates (October 7, 2024, andOctober 14, 2024) with an exercise price equal to the closing price of the company’s common stock as reported by Nasdaq on the grant date ($0.71per share, on both dates).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with the company through the applicable vesting date.

AboutOptinoseOptinoseis a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visitwww.optinose.comor follow us onTwitterandLinkedIn.

Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com267.521.0531

Primary Logo

Source: Optinose, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com